Solid Biosciences (SLDB) EBIAT (2017 - 2024)
Solid Biosciences' EBIAT history spans 8 years, with the latest figure at -$42.6 million for Q4 2024.
- For Q4 2024, EBIAT fell 109.64% year-over-year to -$42.6 million; the TTM value through Dec 2024 reached -$124.7 million, down 29.9%, while the annual FY2024 figure was -$124.7 million, 29.9% down from the prior year.
- EBIAT for Q4 2024 was -$42.6 million at Solid Biosciences, down from -$32.7 million in the prior quarter.
- Across five years, EBIAT topped out at -$15.2 million in Q4 2022 and bottomed at -$42.6 million in Q4 2024.
- The 5-year median for EBIAT is -$21.3 million (2020), against an average of -$23.4 million.
- The largest annual shift saw EBIAT surged 36.69% in 2021 before it crashed 109.64% in 2024.
- A 5-year view of EBIAT shows it stood at -$21.4 million in 2020, then grew by 12.89% to -$18.6 million in 2021, then grew by 18.59% to -$15.2 million in 2022, then plummeted by 34.12% to -$20.3 million in 2023, then tumbled by 109.64% to -$42.6 million in 2024.
- Per Business Quant, the three most recent readings for SLDB's EBIAT are -$42.6 million (Q4 2024), -$32.7 million (Q3 2024), and -$25.1 million (Q2 2024).